"EMT and Cancer Progression and Treatment".
February 28 - March 2, 2010
Westin Arlington Gateway Hotel
Arlington, Virginia
VIEW PROGRAM
CHAIRPERSONS:
John S. Condeelis, Albert Einstein College of Medicine, Bronx, NY
David M. Epstein, OSI Pharmaceuticals, Inc., Farmingdale, NY
Robert A. Weinberg, Whitehead Institute for Biomedical Research,
Cambridge, MA
Underwriting Supporter
Early registration deadline:
Monday, November 30
Abstract submission and
award application deadline:
Monday, December 14
Epithelial to mesenchymal transition (EMT) is a physiological transcriptional reprogramming event used in normal organ development, and is characterized by the combined loss of epithelial cell junctions and cell polarity, and the gain of a mesenchymal phenotype. This reprogramming event allows for organ development through de-differentiation of normal epithelial cells, their migration through an extracellular matrix, and finally re-differentiation, homotypic adhesion and organ growth. EMT and mesenchymal to epithelial transition (MET) processes are now recognized in cancer progression. Understanding EMT/MET at the molecular level promises new insights into mechanisms of progression, detection of metastases, and therapeutic intervention. This conference is dedicated to these goals.
Links to Current
Research in Euchromatin:
Links to
Euchromatin Activator RNA Reviews:
Links to
Euchromatin Activator RNA Research:
Links to Ultrastructural
Probes of DNase I-Sensitive Sites:
Links to
RNA as a Therapeutic Agent:
Links to Hodgkin Lymphoma
Immuno-Pathology:
Links to Activated
T-Lymphocyte Immunotherapy:
Links to Medical
Systems Biology:
Links to Selective
Gene Transcription:
Links to RNA-Induced
Epigenetics:
Links to RNA-Induced
Embryogenesis:
Links to RNA and
Biological Causality:
Links to Reprogramming
and Neoplasia:
A Brief History of Activator RNA:
"Ultrastructural
Probes of Active DNA Sites, and the RNA Activators of DNA".
(PowerPoint Presentation).
Top of Page - Euchromatin
Network - Euchromatin
Research - Research
in Quantitative Radiology
For Further Information and Feedback:
Jeannette A. Hovsepian, M.D.
E-mail: frensasc@ix.netcom.com
Phone: +1 650 367 6483